Search results
Showing 601 to 615 of 734 results for diabet*
Evidence-based recommendations on pulsed-field ablation for atrial fibrillation. This involves using electric field energy to destroy heart cells that are transmitting abnormal electrical impulses.
View recommendations for IPG806Show all sections
When should testing for gestational diabetes take place – in the first or second trimester?
Recommendation ID NG3/2 Question When should testing for gestational diabetes take place – in the first or second trimester? Any...
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
Discontinued Reference number: GID-TA10375
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development Reference number: GID-TA10555 Expected publication date: TBC
Discontinued Reference number: GID-TA10429
Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]
Discontinued Reference number: GID-TA10236
Discontinued Reference number: GID-NG10375
In development Reference number: GID-TA11104 Expected publication date: TBC
Discontinued Reference number: GID-TAG280
Discontinued Reference number: GID-TAG371
Discontinued Reference number: GID-TAG244
Evidence-based recommendations on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus). This involves replacing damaged cartilage with an artificial (synthetic) implant.
View recommendations for IPG727Show all sections
This quality standard is updated and replaced by the quality standards on type 1 diabetes in adults (QS208) and type 2 diabetes in adults (QS209).
Dapagliflozin with insulin for treating type 1 diabetes (TA597)
In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
Discontinued Reference number: GID-TA10177